Windsor Capital Management LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 0.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,733 shares of the healthcare product maker’s stock after buying an additional 4 shares during the period. Windsor Capital Management LLC’s holdings in Abbott Laboratories were worth $375,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ABT. Winfield Associates Inc. grew its holdings in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock worth $116,000 after purchasing an additional 89 shares in the last quarter. V Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $127,000. JFS Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories by 349.0% during the 2nd quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock worth $131,000 after purchasing an additional 2,094 shares in the last quarter. Burt Wealth Advisors grew its holdings in shares of Abbott Laboratories by 14.4% during the 2nd quarter. Burt Wealth Advisors now owns 3,181 shares of the healthcare product maker’s stock worth $154,000 after purchasing an additional 400 shares in the last quarter. Finally, Farmers National Bank grew its holdings in shares of Abbott Laboratories by 1.5% during the 1st quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock worth $158,000 after purchasing an additional 52 shares in the last quarter. 70.64% of the stock is currently owned by institutional investors.

WARNING: “Abbott Laboratories (ABT) Holdings Lifted by Windsor Capital Management LLC” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://theolympiareport.com/2017/11/14/abbott-laboratories-abt-holdings-lifted-by-windsor-capital-management-llc.html.

Several analysts have recently weighed in on ABT shares. Zacks Investment Research lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. J P Morgan Chase & Co started coverage on Abbott Laboratories in a report on Friday, October 6th. They set a “neutral” rating and a $60.00 price objective on the stock. Royal Bank Of Canada reissued a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Tuesday, October 3rd. Cowen and Company set a $68.00 price objective on Abbott Laboratories and gave the stock a “buy” rating in a report on Thursday, October 19th. Finally, Barclays PLC reissued an “overweight” rating and set a $57.00 price objective (up previously from $52.00) on shares of Abbott Laboratories in a report on Saturday, July 22nd. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Abbott Laboratories presently has an average rating of “Buy” and an average target price of $56.81.

In other news, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the sale, the insider now owns 221,488 shares in the company, valued at $10,963,656. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the business’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $56.21, for a total value of $5,430,054.63. Following the sale, the executive vice president now owns 142,082 shares of the company’s stock, valued at approximately $7,986,429.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 408,313 shares of company stock valued at $21,205,356. Corporate insiders own 0.76% of the company’s stock.

Abbott Laboratories (NYSE ABT) opened at $55.30 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $56.69. The stock has a market capitalization of $95,384.93, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. During the same quarter in the previous year, the company posted $0.59 EPS. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. equities research analysts expect that Abbott Laboratories will post 2.5 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a $0.265 dividend. The ex-dividend date is Thursday, October 12th. This represents a $1.06 annualized dividend and a yield of 1.92%. Abbott Laboratories’s payout ratio is 83.47%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.